Dan G. Duda
Impact in
- Cancer Research top 0.1%
- Cancer, Hypoxia, and Metabolism
- Genetics top 0.1%
- Glioma Diagnosis and Treatment
Papers in
- Oncology 89
- Cancer Immunotherapy and Biomarkers 29
- Cancer Cells and Metastasis 17
- Pancreatic and Hepatic Oncology Research 12
-
- Angiogenesis and VEGF in Cancer 54
- Co-authors
- Dai Fukumura (44 shared papers)Jay S. Loeffler (13 shared papers)Tracy T. Batchelor (26 shared papers)Emmanuelle di Tomaso (25 shared papers)A. Gregory Sorensen (8 shared papers)Andrew X. Zhu (24 shared papers)Shom Goel (8 shared papers)Zohreh Amoozgar (6 shared papers)
- Journals
- Journal of Clinical Oncology (31 papers)Cancer Research (16 papers)Proceedings of the National Academy of Sciences (11 papers)Clinical Cancer Research (10 papers)Nature Protocols (7 papers)
- Partner nations
- United StatesJapanGermany
In The Last Decade
Dan G. Duda
222 papers receiving 21.1k citations
Dan G. Duda's Hit Papers
Peers
Comparison fields: 5 of 137
- Cancer Research 4.4k
- Genetics 2.9k
- Oncology 6.8k
- Hepatology 1.8k
- Immunology 3.3k
Countries citing papers authored by Dan G. Duda
This map shows the geographic impact of Dan G. Duda's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dan G. Duda with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dan G. Duda more than expected).
Fields of papers citing papers by Dan G. Duda
This network shows the impact of papers produced by Dan G. Duda. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dan G. Duda. The network helps show where Dan G. Duda may publish in the future.
Co-authors
The 25 scholars most cited alongside Dan G. Duda, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 232 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges Hit paper breakdown → | 2018 | 1438 |
| 2 | AZD2171, a Pan-VEGF Receptor Tyrosine Kinase Inhibitor, Normalizes Tumor Vasculature and Alleviates Edema in Glioblastoma Patients Hit paper breakdown → | 2007 | 1366 |
| 3 | Normalization of the Vasculature for Treatment of Cancer and Other Diseases Hit paper breakdown → | 2011 | 1244 |
| 4 | Angiogenesis in brain tumours Hit paper breakdown → | 2007 | 1071 |
| 5 | Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy Hit paper breakdown → | 2012 | 839 |
| 6 | Lessons from phase III clinical trials on anti-VEGF therapy for cancer Hit paper breakdown → | 2006 | 827 |
| 7 | Anti-angiogenesis for cancer revisited: Is there a role for combinations with immunotherapy? Hit paper breakdown → | 2017 | 529 |
| 8 | Vascular Normalization as an Emerging Strategy to Enhance Cancer Immunotherapy Hit paper breakdown → | 2013 | 519 |
| 9 | 2010 | 477 | |
| 10 | HCC and angiogenesis: possible targets and future directions Hit paper breakdown → | 2011 | 452 |
| 11 | 2009 | 452 | |
| 12 | 2010 | 410 | |
| 13 | 2009 | 383 | |
| 14 | CXCR4 inhibition in tumor microenvironment facilitates anti‐programmed death receptor‐1 immunotherapy in sorafenib‐treated hepatocellular carcinoma in mice Hit paper breakdown → | 2014 | 371 |
| 15 | 2009 | 356 | |
| 16 | Quantum dots spectrally distinguish multiple species within the tumor milieu in vivo Hit paper breakdown → | 2005 | 323 |
| 17 | 2011 | 322 | |
| 18 | Dual Programmed Death Receptor‐1 and Vascular Endothelial Growth Factor Receptor‐2 Blockade Promotes Vascular Normalization and Enhances Antitumor Immune Responses in Hepatocellular Carcinoma Hit paper breakdown → | 2019 | 315 |
| 19 | 2009 | 291 | |
| 20 | 2006 | 276 |
About Dan G. Duda
Dan G. Duda is a scholar working on Oncology, Molecular Biology, Cancer Research, Pulmonary and Respiratory Medicine and Genetics, having authored 232 papers that have together received 21.3k indexed citations. Recurring topics across this work include Angiogenesis and VEGF in Cancer (54 papers), Cancer, Hypoxia, and Metabolism (38 papers), Hepatocellular Carcinoma Treatment and Prognosis (31 papers), Cancer Immunotherapy and Biomarkers (29 papers), Glioma Diagnosis and Treatment (26 papers), Cancer Cells and Metastasis (17 papers), Immune cells in cancer (17 papers) and Pancreatic and Hepatic Oncology Research (12 papers). The work is most often cited by research in Cancer Research (4.4k citations), Genetics (2.9k citations), Oncology (6.8k citations), Hepatology (1.8k citations) and Immunology (3.3k citations). Dan G. Duda has collaborated with scholars based in United States, Japan and Germany. Frequent co-authors include Dai Fukumura, Jay S. Loeffler, Tracy T. Batchelor, Emmanuelle di Tomaso, A. Gregory Sorensen, Andrew X. Zhu, Shom Goel, Zohreh Amoozgar, Lance L. Munn and Jonas Kloepper. Their work appears in journals such as Journal of Clinical Oncology, Cancer Research, Proceedings of the National Academy of Sciences, Clinical Cancer Research and Nature Protocols.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.